CLAIM CARD
Within the corpus, notable tensions exist between preclinical evidence and human trial outcomes. Shindyapina 2022's finding that developmental rapamycin extends lifespan in mice contrasts with Elliehausen 2025's emphasis on intermittent dosing to avoid glucose disruptions while maintaining exercise benefits. These disagreements reflect the broader pattern that mechanistic plausibility in animal models has not consistently translated to clear cardiometabolic benefit in human studies, as also noted by Impacts 2027's ongoing investigation in older adults.
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025